Tags

Type your tag names separated by a space and hit enter

Low dose oral desmopressin for nocturnal polyuria in patients with benign prostatic hyperplasia: a double-blind, placebo controlled, randomized study.
J Urol. 2011 Jan; 185(1):219-23.JU

Abstract

PURPOSE

We evaluated the long-term efficacy and safety of low dose oral desmopressin in elderly patients with benign prostatic hyperplasia with more than nocturnal voids and nocturnal polyuria more than 30% of total daily urine volume.

MATERIALS AND METHODS

Eligible patients with benign prostatic hyperplasia older than 65 years with nocturia, nocturnal polyuria and International Prostate Symptom Score 14 or greater were included in the study. All patients received placebo or 0.1 mg desmopressin orally at bedtime. Patients were required to visit the outpatient clinic from the first visit, and after 1, 3, 6 and 12 months of treatment. Patients maintained flow volume charts and used diaries to record voiding data throughout the study. During followup urinalysis, urine sodium, urine osmolality, serum electrolytes, prostate specific antigen, International Prostate Symptom Score, quality of life, transrectal ultrasonography of prostate, uroflowmetry and post-void residual urine volume were performed at each visit.

RESULTS

A total of 115 patients were enrolled in the study and randomized as 58 in the placebo group and 57 in the desmopressin group. Desmopressin significantly decreased nocturnal urine output and the number of nocturia episodes, and prolonged the first sleep period (p < 0.01). Compared to before treatment desmopressin gradually decreased serum sodium and induced statistically but not clinically significant hyponatremia after 12 months of treatment. No serious systemic complications were found during medication.

CONCLUSIONS

Low dose oral desmopressin is an effective and well tolerated treatment for nocturnal polyuria in the lower urinary tract symptoms of patients with benign prostatic hyperplasia. Long-term desmopressin therapy gradually decreases serum sodium and it might induce hyponatremia even in patients without initial hyponatremia. For long-term desmopressin administration serum sodium should be assessed carefully, at least at 1 week after treatment.

Authors+Show Affiliations

Department of Surgery, Saint Martin De Porres Hospital, Chiayi, Taiwan, R.O.C. jing@stm.org.twNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article
Randomized Controlled Trial

Language

eng

PubMed ID

21074790

Citation

Wang, Chung-Jing, et al. "Low Dose Oral Desmopressin for Nocturnal Polyuria in Patients With Benign Prostatic Hyperplasia: a Double-blind, Placebo Controlled, Randomized Study." The Journal of Urology, vol. 185, no. 1, 2011, pp. 219-23.
Wang CJ, Lin YN, Huang SW, et al. Low dose oral desmopressin for nocturnal polyuria in patients with benign prostatic hyperplasia: a double-blind, placebo controlled, randomized study. J Urol. 2011;185(1):219-23.
Wang, C. J., Lin, Y. N., Huang, S. W., & Chang, C. H. (2011). Low dose oral desmopressin for nocturnal polyuria in patients with benign prostatic hyperplasia: a double-blind, placebo controlled, randomized study. The Journal of Urology, 185(1), 219-23. https://doi.org/10.1016/j.juro.2010.08.095
Wang CJ, et al. Low Dose Oral Desmopressin for Nocturnal Polyuria in Patients With Benign Prostatic Hyperplasia: a Double-blind, Placebo Controlled, Randomized Study. J Urol. 2011;185(1):219-23. PubMed PMID: 21074790.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Low dose oral desmopressin for nocturnal polyuria in patients with benign prostatic hyperplasia: a double-blind, placebo controlled, randomized study. AU - Wang,Chung-Jing, AU - Lin,Yu-Nan, AU - Huang,Shi-Wei, AU - Chang,Chien-Hsing, Y1 - 2010/11/13/ PY - 2010/04/29/received PY - 2010/11/16/entrez PY - 2010/11/16/pubmed PY - 2011/1/7/medline SP - 219 EP - 23 JF - The Journal of urology JO - J Urol VL - 185 IS - 1 N2 - PURPOSE: We evaluated the long-term efficacy and safety of low dose oral desmopressin in elderly patients with benign prostatic hyperplasia with more than nocturnal voids and nocturnal polyuria more than 30% of total daily urine volume. MATERIALS AND METHODS: Eligible patients with benign prostatic hyperplasia older than 65 years with nocturia, nocturnal polyuria and International Prostate Symptom Score 14 or greater were included in the study. All patients received placebo or 0.1 mg desmopressin orally at bedtime. Patients were required to visit the outpatient clinic from the first visit, and after 1, 3, 6 and 12 months of treatment. Patients maintained flow volume charts and used diaries to record voiding data throughout the study. During followup urinalysis, urine sodium, urine osmolality, serum electrolytes, prostate specific antigen, International Prostate Symptom Score, quality of life, transrectal ultrasonography of prostate, uroflowmetry and post-void residual urine volume were performed at each visit. RESULTS: A total of 115 patients were enrolled in the study and randomized as 58 in the placebo group and 57 in the desmopressin group. Desmopressin significantly decreased nocturnal urine output and the number of nocturia episodes, and prolonged the first sleep period (p < 0.01). Compared to before treatment desmopressin gradually decreased serum sodium and induced statistically but not clinically significant hyponatremia after 12 months of treatment. No serious systemic complications were found during medication. CONCLUSIONS: Low dose oral desmopressin is an effective and well tolerated treatment for nocturnal polyuria in the lower urinary tract symptoms of patients with benign prostatic hyperplasia. Long-term desmopressin therapy gradually decreases serum sodium and it might induce hyponatremia even in patients without initial hyponatremia. For long-term desmopressin administration serum sodium should be assessed carefully, at least at 1 week after treatment. SN - 1527-3792 UR - https://www.unboundmedicine.com/medline/citation/21074790/Low_dose_oral_desmopressin_for_nocturnal_polyuria_in_patients_with_benign_prostatic_hyperplasia:_a_double_blind_placebo_controlled_randomized_study_ L2 - https://www.jurology.com/doi/10.1016/j.juro.2010.08.095?url_ver=Z39.88-2003&amp;rfr_id=ori:rid:crossref.org&amp;rfr_dat=cr_pub=pubmed DB - PRIME DP - Unbound Medicine ER -